Innovative drugs reformer Bi out amid China vaccines scandal

Thursday’s resignation of Jingquan Bi, party secretary of the State Administration of Market Supervision, means that China has lost a champion of innovative biopharma products; however, it remains to be seen whether his departure will change the pace of regulatory innovation and the appetite for innovative drugs in the country.

Following a meeting of the Politburo Standing Committee presided over by Chinese President

Read the full 637 word article

User Sign In